| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8447170 | European Journal of Cancer | 2011 | 11 Pages |
Abstract
This trial, conducted prior to the reporting of registrational phase III trials, found that sorafenib did not significantly prolong TTP in patients who responded to TACE. This may have been due to delays in starting sorafenib after TACE and/or low daily sorafenib doses.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Masatoshi Kudo, Kazuho Imanaka, Nobuyuki Chida, Kohei Nakachi, Won-Young Tak, Tadatoshi Takayama, Jung-Hwan Yoon, Takeshi Hori, Hiromitsu Kumada, Norio Hayashi, Shuichi Kaneko, Hirohito Tsubouchi, Dong Jin Suh, Junji Furuse, Takuji Okusaka,